TY - JOUR
T1 - Searching for Explanations for Cryptogenic Stroke in the Young
T2 - Revealing the Triggers, Causes, and Outcome (SECRETO): Rationale and design
AU - Putaala, Jukka
AU - Martinez-Majander, Nicolas
AU - Saeed, Sahrai
AU - Yesilot, Nilufer
AU - Jäkälä, Pekka
AU - Nerg, Ossi
AU - Tsivgoulis, Georgios
AU - Numminen, Heikki
AU - Gordin, Daniel
AU - von Sarnowski, Bettina
AU - Waje-Andreassen, Ulrike
AU - Ylikotila, Pauli
AU - Roine, Risto O.
AU - Zedde, Marialuisa
AU - Huhtakangas, Juha
AU - Fonseca, Catarina
AU - Redfors, Petra
AU - de Leeuw, Frank Erik
AU - Pezzini, Alessandro
AU - Kõrv, Janika
AU - Schneider, Siim
AU - Tanislav, Christian
AU - Enzinger, Christian
AU - Jatuzis, Dalius
AU - Siegerink, Bob
AU - Martínez-Sánchez, Patricia
AU - Grau, Armin J.
AU - Palm, Frederick
AU - Groop, Per Henrik
AU - Lanthier, Sylvain
AU - Ten Cate, Hugo
AU - Pussinen, Pirkko
AU - Paju, Susanna
AU - Sinisalo, Juha
AU - Lehto, Mika
AU - Lindgren, Arne
AU - Ferro, José
AU - Kittner, Steven
AU - Fazekas, Franz
AU - Gerdts, Eva
AU - Tatlisumak, Turgut
PY - 2017/6/1
Y1 - 2017/6/1
N2 - Background: Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented causality like patent foramen ovale and coagulopathies. Key hypotheses/aims: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions. Design: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) is a prospective multi-centre case–control study enrolling patients aged 18–49 years hospitalised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient–control pairs enrolled by the end of 2018. Summary: SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will provide new directions for therapy development for these patients. First results are anticipated in 2019.
AB - Background: Worldwide, about 1.3 million annual ischaemic strokes (IS) occur in adults aged <50 years. Of these early-onset strokes, up to 50% can be regarded as cryptogenic or associated with conditions with poorly documented causality like patent foramen ovale and coagulopathies. Key hypotheses/aims: (1) Investigate transient triggers and clinical/sub-clinical chronic risk factors associated with cryptogenic IS in the young; (2) use cardiac imaging methods exceeding state-of-the-art to reveal novel sources for embolism; (3) search for covert thrombosis and haemostasis abnormalities; (4) discover new disease pathways using next-generation sequencing and RNA gene expression studies; (5) determine patient prognosis by use of phenotypic and genetic data; and (6) adapt systems medicine approach to investigate complex risk-factor interactions. Design: Searching for Explanations for Cryptogenic Stroke in the Young: Revealing the Etiology, Triggers, and Outcome (SECRETO; NCT01934725) is a prospective multi-centre case–control study enrolling patients aged 18–49 years hospitalised due to first-ever imaging-proven IS of undetermined etiology. Patients are examined according to a standardised protocol and followed up for 10 years. Patients are 1:1 age- and sex-matched to stroke-free controls. Key study elements include centralised reading of echocardiography, electrocardiography, and neurovascular imaging, as well as blood samples for genetic, gene-expression, thrombosis and haemostasis and biomarker analysis. We aim to have 600 patient–control pairs enrolled by the end of 2018. Summary: SECRETO is aiming to establish novel mechanisms and prognosis of cryptogenic IS in the young and will provide new directions for therapy development for these patients. First results are anticipated in 2019.
KW - Brain infarction
KW - echocardiography
KW - electrocardiography
KW - embolism
KW - middle aged
KW - paradoxical embolism
KW - patent foramen ovale
KW - prognosis
KW - risk factors
KW - stroke
KW - thrombosis
KW - young adult
U2 - 10.1177/2396987317703210
DO - 10.1177/2396987317703210
M3 - Article
AN - SCOPUS:85060508142
SN - 2396-9873
VL - 2
SP - 116
EP - 125
JO - European Stroke Journal
JF - European Stroke Journal
IS - 2
ER -